Telbivudine
- Generic Name
- Telbivudine
- Drug Type
- Small Molecule
- Chemical Formula
- C10H14N2O5
- CAS Number
- 3424-98-4
- Unique Ingredient Identifier
- 2OC4HKD3SF
- Background
Telbivudine is a synthetic thymidine nucleoside analog with specific activity against the hepatitis B virus. Telbivudine is orally administered, with good tolerance, lack of toxicity and no dose-limiting side effects.
- Indication
For the treatment of chronic hepatitis B in adult and adolescent patients ≥16 years of age with evidence of viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease.
- Associated Conditions
- Chronic Hepatitis B Infection
Renoprotective Effects of Telbivudine in Chronic Hepatitis B
- First Posted Date
- 2018-12-19
- Last Posted Date
- 2018-12-19
- Lead Sponsor
- The University of Hong Kong
- Target Recruit Count
- 31
- Registration Number
- NCT03778567
- Locations
- 🇭🇰
Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong
The Safety of Anti-viral Therapy in Preventing HBV MTCT in Pregnant Women After Discontinuation
- Conditions
- Hepatitis B, Chronic
- Interventions
- First Posted Date
- 2018-03-19
- Last Posted Date
- 2018-08-29
- Lead Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
- Target Recruit Count
- 111
- Registration Number
- NCT03468907
Renal Function Improvement in HBsAg Positive Kidney Transplantation Patients Under Telbivudine Treatment.
- Conditions
- HBsAg-positive Renal Allograft Recipients
- Interventions
- First Posted Date
- 2016-09-09
- Last Posted Date
- 2016-09-09
- Lead Sponsor
- National Taiwan University Hospital
- Target Recruit Count
- 19
- Registration Number
- NCT02894554
EFFORT Further Extension Study
- Conditions
- Hepatitis B, Chronic
- Interventions
- First Posted Date
- 2016-07-07
- Last Posted Date
- 2016-07-07
- Lead Sponsor
- Nanfang Hospital, Southern Medical University
- Target Recruit Count
- 130
- Registration Number
- NCT02826070
- Locations
- 🇨🇳
Beijing Ditan Hospital, Beijing, Beijing, China
🇨🇳People's Hospital of Beijing University, Beijing, Beijing, China
🇨🇳The Third Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China
Tenofovir Versus Tenofovir + Telbivudine for Chronic Hepatitis B
- First Posted Date
- 2016-05-17
- Last Posted Date
- 2019-03-18
- Lead Sponsor
- Seng Gee Lim
- Target Recruit Count
- 146
- Registration Number
- NCT02774837
- Locations
- 🇸🇬
National University Hospital, Singapore, Singapore
A Clinical Trial on Hepatitis B Vaccine Activated-Dendritic Cells Combined With Anti-HBV Drugs in CHB
- Conditions
- Chronic Hepatitis B
- Interventions
- Biological: HPDC-T cells & EntecavirDrug: HPDC-T cells & IFN-a-2aDrug: IFN-a-2aDrug: HPDC-T cells & Telbivudine
- First Posted Date
- 2015-11-26
- Last Posted Date
- 2015-11-26
- Lead Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
- Target Recruit Count
- 450
- Registration Number
- NCT02615639
Replacement of Lamivudine by Telbivudine to Improve Renal Function
- Conditions
- Virus DiseasesDisorder Related to TransplantationInjury Due to Exposure to External Cause
- Interventions
- First Posted Date
- 2015-05-19
- Last Posted Date
- 2017-02-07
- Lead Sponsor
- Chang Gung Memorial Hospital
- Target Recruit Count
- 120
- Registration Number
- NCT02447705
The Effect of Anti-viral Drugs Used in Late Pregnancy on Long-term Development of Children
- Conditions
- the Safety of Anti-viral Drugs Used in Late Pregnancy
- Interventions
- First Posted Date
- 2014-11-26
- Last Posted Date
- 2014-11-26
- Lead Sponsor
- Beijing Ditan Hospital
- Target Recruit Count
- 400
- Registration Number
- NCT02301650
Efficacy of Antiviral Therapy in Pregnancy in Preventing Vertical Transmission of HBV in Mothers With a High Viral Load
- Conditions
- Immune Globulin, Prophylaxis, Telbuvidine, Vaccine
- Interventions
- First Posted Date
- 2014-10-01
- Last Posted Date
- 2014-10-01
- Lead Sponsor
- Beijing Ditan Hospital
- Target Recruit Count
- 600
- Registration Number
- NCT02253485
Study of Efficacy and Safety, Tolerability and Pharmacokinetics of Telbivudine in Children and Adolescents With Compensated Chronic Hepatitis B Virus Infection
- First Posted Date
- 2014-02-07
- Last Posted Date
- 2019-09-10
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 53
- Registration Number
- NCT02058108
- Locations
- 🇺🇦
Novartis Investigative Site, Vinnytsia, Ukraine
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.